证券日报网讯 12月18日，国际医学在互动平台回答投资者提问时表示，公司非公开发行股票符合公司 发展战略，且均经过董事会、股东会审议通过，并获得证券监管部门核准。公司通过非公开发行募集资 金，支持了公司业务发展，增强了公司的经营能力，有利于公司长远发展和全体股东的利益。 （文章来源：证券日报） ...

Core Viewpoint - The actual controller and chairman of Gaode Infrared, Huang Li, plans to reduce his shareholding due to funding needs for another listed company, with a maximum reduction of 128,122,083 shares, accounting for 3.00% of the total share capital [1][2]. Shareholding Reduction Plan - Huang Li currently holds 1,157,349,375 shares, representing 27.10% of the total share capital [1]. - The planned reduction will occur within three months after the announcement, excluding the trading window, through centralized bidding and block trading [1]. - The maximum shares to be reduced through centralized bidding is 42,707,361 shares (1.00% of total share capital), while block trading will account for up to 85,414,722 shares (2.00% of total share capital) [1]. Financial Implications - Based on the closing price of 12.58 yuan on November 18, the cash amount Huang Li could realize from the share reduction is approximately 1.612 billion yuan [1]. - The company has previously raised approximately 2.5 billion yuan through a non-public offering of 84,260,195 shares at a price of 29.67 yuan per share, with a net amount received of about 2.477 billion yuan after deducting underwriting fees [2].

Core Points - Aolide (688378) has terminated the review status of its simplified procedure for non-public stock issuance [2] - The company planned to issue up to 15.6897 million shares, aiming to raise approximately 270 million yuan [2] - The sponsor for this issuance was Dongfang Securities Co., Ltd. [2] Summary by Sections - **Issuance Plan** - Aolide intended to issue shares to specific investors, with a maximum issuance of 15.6897 million shares [2] - The expected fundraising amount was 270 million yuan [2] - **Regulatory Considerations** - The company announced the decision to adjust its financing plan based on regulatory considerations and its business development strategy [2] - Aolide decided to withdraw the application documents related to the simplified procedure for stock issuance and plans to reapply at an appropriate time [2]

Core Viewpoint - The actual controller of Jingda Co., Ltd. plans to reduce his shareholding due to personal financial needs, which may impact the company's stock performance and investor sentiment [1] Group 1: Shareholding Reduction Plan - The actual controller, Li Guangrong, intends to reduce his holdings by up to 64,300,000 shares, representing no more than 3% of the total share capital [1] - The reduction will occur through centralized bidding and block trading, with a maximum of 1% through centralized bidding and 2% through block trading [1] - The reduction period is set for three months starting from 15 trading days after the announcement, with no reductions during the window period [1] Group 2: Financial Implications - Based on the closing price of 10.55 yuan per share on October 16, 2025, the estimated amount from this reduction is approximately 678 million yuan [1] - As of the announcement date, Li Guangrong holds 83,333,333 shares, accounting for 3.88% of the total share capital [1] - Together with his associates, they hold a total of 199,333,390 shares, which is 9.27% of the total share capital [1] Group 3: Recent Fundraising Activities - Jingda Co., Ltd. plans to issue convertible bonds to raise up to 956 million yuan for various projects, including a 40,000-ton new energy copper-based electromagnetic wire project [2] - In the past five years, the company has raised funds twice, totaling 1.0845 billion yuan [3] - The company conducted a non-public stock issuance in 2022, raising 297.5 million yuan, which has been fully utilized by 2023 [4]

Group 1 - The core point of the article is that Zhuoyue New Energy (688196) has had its application for a private placement of shares approved and registered as effective [2] - The company plans to raise funds amounting to 300 million yuan through a simplified procedure aimed at specific investors [2] - The raised funds will be utilized for a project to produce 100,000 tons of hydrocarbon biodiesel annually [2] Group 2 - The underwriting institution for this issuance is Huafu Securities Co., Ltd [2]

Core Viewpoint - Jiuhua Tourism (603199) has terminated its non-public stock issuance project due to changes in market conditions and company development plans [1] Group 1: Project Termination - On September 16, the review status of Jiuhua Tourism's non-public stock issuance project was changed to "terminated" [1] - The company and its sponsor, Huazheng Securities (600909), submitted an application to withdraw the stock issuance application and the sponsorship work on September 12 [1] - The company’s board of directors approved the termination of the A-share issuance to specific targets during a meeting on September 10 [1] Group 2: Reasons for Termination - The decision to terminate the stock issuance was made after comprehensive consideration of current market environment changes and the company's development plans [1] - The company emphasized that the decision was reached after thorough communication and careful deliberation among relevant parties [1]

Core Viewpoint - Keleke (002782.SZ) announced the completion of the share reduction plan by its controlling shareholder and concerted parties, with a total of 9,399,082 shares reduced, amounting to approximately 139 million yuan in total [1][2][3] Share Reduction Details - From August 27 to September 2, 2025, Keleke Technology reduced 2,439,982 shares at an average price of 16.62 yuan per share [2] - From July 17, 2025, Keleke Technology reduced 3,648,000 shares through block trading at an average price of 12.39 yuan per share [2] - During the reduction period from July 17 to September 2, 2025, the total shares reduced by both Shengyan Investment and Keleke Technology amounted to 9,399,082 shares, with a total reduction amount of approximately 139 million yuan [3] Shareholding Changes - After the reduction, the combined shareholding of Shengyan Investment and Keleke Technology decreased from 57.42% to 57.41% [1] - The total amount reduced by Shengyan Investment from August 27 to August 29, 2025, was 2,441,100 shares at an average price of 16.43 yuan per share, and 870,000 shares at an average price of 14.99 yuan per share [1][4] Fundraising Activities - Keleke was approved for a non-public offering of up to 85,200,000 new shares, having issued 42,734,227 shares at a price of 11.45 yuan per share, raising approximately 489 million yuan [4] - In a subsequent offering, Keleke was approved for a non-public issuance of up to 47,672,322 shares, having issued 13,646,186 shares at a price of 16.52 yuan per share, raising approximately 225 million yuan [5] - The total amount raised from both fundraising activities was approximately 714 million yuan [6]

Financial Performance - The company's revenue for the first half of 2025 reached 51.6 billion CNY, a year-on-year increase of 4% [2] - The net profit attributable to shareholders was 5.7 billion CNY, showing a turnaround with a growth of 19.7% compared to the previous year [2] - The feed business generated a net profit of 6 billion CNY, with a total sales volume of 1.3 million tons, reflecting a year-on-year growth of 13% [2][3] Feed Business Strategy - The company aims to expand its scale by targeting key customers and optimizing product offerings, with customized feed sales to major clients increasing by over 20% [4] - To mitigate trade war impacts, the company is enhancing external procurement and optimizing raw material sourcing, achieving a 96% usage rate of its online sourcing system in the first half of 2025 [4] - The overseas feed capacity has exceeded 7 million tons, with plans to add 3-4 million tons in the next 3-5 years, and overseas sales grew by 18% in the first half of 2025 [5] Swine Business Highlights - The company reported a 60% reduction in ASF incidence in the first half of 2025, with significant improvements in production metrics [6] - Average piglets per litter increased to 11.2, and the average PSY (pigs weaned per sow) improved to 25.4, both showing enhancements from 2024 [6][8] - The average cost of production dropped to 13.1 CNY/kg, with some regions achieving costs below 12 CNY/kg [8] Stock Issuance and Regulatory Compliance - The non-public stock issuance project is progressing well, with major issues resolved, and the company plans to submit updated materials to the exchange soon [9] - The company is actively participating in national capacity regulation discussions, believing these policies will support long-term industry health [10] Future Outlook and Cost Management - The company aims to maintain a stable breeding stock of 760,000 sows and plans to keep annual slaughter volumes between 16-17 million heads [11] - Cost reduction strategies include enhancing disease control, optimizing breeding management, and improving production efficiency, with expectations for further cost reductions by year-end [14] - The company anticipates stable pork prices in the medium to long term, with limited downward pressure [15] International Operations and Profitability - The average profit per ton of overseas feed is over 180 CNY, significantly higher than domestic profits [18] - The company is focusing on expanding in regions with stable political and economic environments, prioritizing markets with high potential for growth [18]

Core Viewpoint - The announcement reveals that the controlling shareholder and its concerted parties of Keleke (002782.SZ) have reduced their shareholding, triggering a change in equity that touches upon the 1% integer multiple threshold [1][2]. Shareholding Changes - Ganzhou Shengyan Investment Co., Ltd. (referred to as "Shengyan Investment") reduced its holdings by 3,311,100 shares, accounting for 0.67% of the total share capital, from August 26 to August 29, 2025 [1][2]. - Keleke Technology Co., Ltd. (referred to as "Keleke Technology") reduced its holdings by 2,399,982 shares, accounting for 0.48% of the total share capital, from August 27 to September 1, 2025 [1][2]. - The combined reduction from both parties amounts to 5,711,082 shares, representing 1.15% of the total share capital, decreasing their total holdings from 290,508,277 shares to 284,797,195 shares, and their ownership percentage from 58.57% to 57.42% [2]. Financial Impact - Shengyan Investment realized approximately CNY 54.50 million from the share reduction, calculated at an average price of CNY 16.46 per share [1]. - Keleke Technology realized approximately CNY 39.74 million from its share reduction, calculated at an average price of CNY 16.56 per share [1]. - The total cashing out from both parties amounts to approximately CNY 94.24 million [1]. Previous Share Reduction Plans - A prior announcement indicated that Shengyan Investment and Keleke Technology planned to reduce their holdings by up to 14,646,960 shares, or 3% of the total share capital, within three months from the disclosure date [3].

Core Viewpoint - The major shareholder of Dabo Medical, Dabo International Investment Co., Ltd., plans to reduce its stake in the company, which may impact the stock's performance and investor sentiment [1][2][3]. Shareholder Reduction Plan - Dabo International holds 82,926,901 shares, representing 20.03% of the total share capital, and plans to reduce its holdings by up to 8,280,390 shares, or 2.00% of the total share capital, within three months from the announcement date [1]. - The reduction will occur through centralized bidding or block trading methods [1]. Shareholding Changes - From October 17, 2022, to September 1, 2023, Dabo International's shareholding decreased by 8,280,000 shares (2.00%), while Zhao Shaomei's shareholding decreased by 1,600,000 shares (0.39%), totaling a combined reduction of 9,880,000 shares (2.39%) [2]. Completion of Reduction Plan - As of December 23, 2023, Dabo International completed its reduction plan, having sold a total of 9,137,389 shares, which is 2.21% of the total share capital, for a total amount of 264 million yuan [3]. - The shares were sold at an average price of 38.80 yuan during the last trading period [3]. Company Control and Structure - The actual controllers of Dabo Medical are Lin Zhixiong and Lin Zhijun, who are siblings, while Zhao Shaomei is the mother-in-law of Lin Zhijun [3]. - Dabo International serves as the holding platform for the actual controllers, with its main asset being a 25.57% stake in Dabo Medical [3]. Fundraising Activities - Dabo Medical raised 496.32 million yuan through a non-public offering of 12 million shares at a price of 41.36 yuan per share, with net proceeds amounting to 487.22 million yuan after deducting related expenses [4].